Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma

Ito,Keiichi; Yoshii,Hidehiko; Asano,Takako; Horiguchi,Akio; Sumitomo,Makoto; Hayakawa,Masamichi; Asano,Tomohiko

doi:10.3892/etm.2012.513

Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma

Authors:
- Keiichi Ito
- Hidehiko Yoshii
- Takako Asano
- Akio Horiguchi
- Makoto Sumitomo
- Masamichi Hayakawa
- Tomohiko Asano
View Affiliations

Affiliations: Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
Published online on: March 13, 2012 https://doi.org/10.3892/etm.2012.513
Pages: 937-944

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erythropoietin (EPO) expression and EPO receptor (EpoR) expression have been demonstrated in various malignant tumors. EPO-EpoR signaling can activate several downstream signal transduction pathways that enhance tumor aggressiveness. The present study was undertaken to evaluate the impact of overexpression of EpoR and elevated serum EPO (sEPO) levels on the clinicopathological features and prognosis of patients with renal cell carcinoma (RCC). EpoR expression was evaluated immunohistochemically in 56 patients. Tumors with a staining intensity greater than that of surrounding proximal tubules were defined as tumors with high EpoR expression. The association between EpoR expression levels and various clinicopathological factors was analyzed. sEPO levels were determined in 138 patients and its correlation to clinicopathological factors was also analyzed, and EpoR expression was determined in surgical specimens removed from 47 of those 138 patients. Patients with high EpoR expression and patients with sEPO elevation had clinicopathological features less favorable than those of other patients. Tumors demonstrating high EpoR expression had a significantly higher number of Ki-67-positive cells compared to those with low EpoR expression. Tumor assemblies in microvessels demonstrated high EpoR expression. Patients whose tumors demonstrated high EpoR expression and those with sEPO elevation had a significantly lower survival rate compared to other patients, and patients with both high EpoR expression and sEPO elevation had an extremely poor prognosis. Microvascular invasion was an independent factor associated with sEPO elevation, suggesting that EPO-EpoR signaling might be important in RCC metastasis. EPO-EpoR signaling may be involved in tumor growth and progression in RCC and the combination of EpoR expression and sEPO levels may effectively predict clinical outcome.

View Figures

View References

1.	Da Silva JL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P and Varet B: Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood. 75:577–582. 1990.PubMed/NCBI
2.	Westenfelder C and Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58:647–657. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res. 12:332–339. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Ljungberg B, Rasmuson T and Grankvist K: Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol. 21:160–163. 1992.PubMed/NCBI
5.	Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, Relph K, Syrigos KN and Pandha H: Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int. 100:291–294. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, Girard P, Validire P, Breau JL, Bernaudin JF and Soria JC: Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res. 13:4825–4831. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Acs G, Xu X, Chu C, Acs P and Verma A: Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 100:2376–2386. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL and Grandis JR: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 24:4442–4449. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Lester RD, Jo M, Campana WM and Gonias SL: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 280:39273–39277. 2005. View Article : Google Scholar
10.	Tilbrook PA, Colley SM, McCarthy DJ, Marais R and Klinken SP: Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch Biochem Biophys. 396:128–132. 2001. View Article : Google Scholar : PubMed/NCBI
11.	Gong K, Zhang N, Zhang Z and Na Y: Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther. 5:582–585. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Papworth K, Bergh A, Grankvist K, Ljungberg B and Rasmuson T: Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol. 30:86–92. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Ito K, Yoshii H, Asakuma J, Sato A, Horiguchi A, Sumitomo M, Hayakawa M and Asano T: Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens. Jpn J Clin Oncol. 39:588–594. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M and Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol. 172:718–722. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Sturiale A, Campo S, Crascì E, Coppolino G, Bolignano D, Grasso G and Buemi M: Erythropoietin and its lost receptor. Nephrol Dial Transplant. 22:1484–1485. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T and Hayakawa M: Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 62:4176–4179. 2002.PubMed/NCBI
17.	Islam AH, Ehara T, Kato H, Hayama M, Kobayashi S, Igawa Y and Nishizawa O: Calponin h1 expression in renal tumor vessels: correlations with multiple pathological factors of renal cell carcinoma. J Urol. 171:1319–1323. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R and Vacca A: Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 42:246–250. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Vesey DA, Cheung C, Pat B, Endre Z, Gobé G and Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 19:348–355. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Li J, Vesey DA, Johnson DW and Gobe G: Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther. 6:1944–1950. 2007. View Article : Google Scholar : PubMed/NCBI